-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-06-26
BETRF:OTC- (USD)
COMMON STOCK | Biotechnology |
Last Closing
USD 0.08Change
0.00 (-4.76)%Market Cap
USD 0.01BVolume
6.20KVerdict
Verdict
Values as of: 2024-06-26
COMMON STOCK | Biotechnology |
Last Closing
USD 0.08Change
0.00 (-4.76)%Market Cap
USD 0.01BVolume
6.20KVerdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
NONOF | Novo Nordisk A/S |
N/A |
USD 641.36B |
CMXHF | CSL Limited |
N/A |
USD 95.97B |
CSLLY | CSL Ltd |
N/A |
USD 95.20B |
UCBJF | UCB SA |
N/A |
USD 28.35B |
UCBJY | UCB SA ADR |
N/A |
USD 27.94B |
ARGNF | argenx SE |
N/A |
USD 23.04B |
GNMSF | Genmab A/S |
N/A |
USD 16.66B |
IVBIY | IVBIY |
N/A |
USD 8.23B |
SBMFF | Sino Biopharmaceutical Limited |
N/A |
USD 6.87B |
REGMF | RemeGen Co. Ltd |
N/A |
USD 6.81B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
CRAK | VanEck Oil Refiners ETF | 7.87 % | 0.60 % |
N/A |
USD 0.03B |
XSOE | WisdomTree Emerging Marke.. | 1.73 % | 0.32 % |
N/A |
USD 2.01B |
GMF | SPDR® S&P Emerging Asia .. | 1.67 % | 0.49 % |
N/A |
USD 0.34B |
SPEM | SPDR® Portfolio Emerging.. | 1.46 % | 0.12 % |
N/A |
USD 9.05B |
AVEM | Avantis® Emerging Market.. | 0.87 % | 0.00 % |
N/A |
USD 5.77B |
Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 66.67% | 84% | B | 90% | A- | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 66.67% | 85% | B | 90% | A- | ||
Trailing 12 Months | |||||||
Capital Gain | 40.35% | 82% | B | 84% | B | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 40.35% | 82% | B | 83% | B | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | -32.47% | 16% | F | 6% | D- | ||
Dividend Return | -32.47% | 16% | F | 6% | D- | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 40.46% | 74% | C | 58% | F | ||
Risk Adjusted Return | -80.26% | 19% | F | 8% | B- | ||
Market Capitalization | 0.01B | 53% | F | 39% | F |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The stock is trading high compared to its peers median on a price to book value basis.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.